Real-world clinical outcomes of treatment with molnupiravir for patients with mild-to-moderate coronavirus disease 2019 during the Omicron variant pandemic

[1]  Y. Kurahashi,et al.  Large-scale serosurveillance of COVID-19 in Japan: Acquisition of neutralizing antibodies for Delta but not for Omicron and requirement of booster vaccination to overcome the Omicron’s outbreak , 2022, PloS one.

[2]  A. Cathcart,et al.  Effect of Sotrovimab on Hospitalization or Death Among High-risk Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial. , 2022, JAMA.

[3]  Y. Liu,et al.  The effective reproductive number of the Omicron variant of SARS-CoV-2 is several times relative to Delta , 2022, Journal of Travel Medicine.

[4]  Shinji Watanabe,et al.  Efficacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2 , 2022, The New England journal of medicine.

[5]  Y. Liu,et al.  The effective reproductive number of the Omicron variant of SARS-CoV-2 is several times relative to Delta , 2022, Journal of travel medicine.

[6]  Kwang Su Kim,et al.  Different efficacies of neutralizing antibodies and antiviral drugs on SARS-CoV-2 Omicron subvariants, BA.1 and BA.2 , 2022, bioRxiv.

[7]  K. Rosenke,et al.  Molnupiravir (MK-4482) is efficacious against Omicron and other SARS-CoV-2 variants in the Syrian hamster COVID-19 model , 2022, bioRxiv.

[8]  M. Baniecki,et al.  Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19 , 2022, The New England journal of medicine.

[9]  A. Harries,et al.  Faculty Opinions recommendation of Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients. , 2022, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.

[10]  D. Fremont,et al.  An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies , 2022, Nature Medicine.

[11]  M. Wass,et al.  Reduced interferon antagonism but similar drug sensitivity in Omicron variant compared to Delta variant of SARS-CoV-2 isolates , 2022, Cell Research.

[12]  H. Jäck,et al.  The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic , 2021, Cell.

[13]  J. Butterton,et al.  Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients , 2021, The New England journal of medicine.

[14]  E. Callaway.  Heavily mutated Omicron variant puts scientists on alert , 2021, Nature.

[15]  K. Shiraki,et al.  Evaluation of Biomarkers of Severity in Patients with COVID-19 Infection , 2021, Journal of clinical medicine.

[16]  Mei Peng,et al.  Role of Hypertension on the Severity of COVID-19: A Review , 2021, Journal of cardiovascular pharmacology.

[17]  T. Kawahara,et al.  Using Propensity Scores for Causal Inference: Pitfalls and Tips , 2021, Journal of epidemiology.

[18]  R. Pranata,et al.  Dyslipidemia Increases the Risk of Severe COVID-19: A Systematic Review, Meta-analysis, and Meta-regression , 2021, Clinical medicine insights. Endocrinology and diabetes.

[19]  John D. Davis,et al.  REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19 , 2020, The New England journal of medicine.

[20]  P. Dormitzer,et al.  Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine , 2020, The New England journal of medicine.

[21]  S. Rowland-Jones,et al.  Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus , 2020, Cell.

[22]  E. Stuart,et al.  Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies , 2015, Statistics in medicine.

[23]  P. Austin,et al.  Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies , 2010, Pharmaceutical statistics.